| Identification | Back Directory | [Name]
Tussilagone | [CAS]
104012-37-5 | [Synonyms]
L 652469
Tussilagone
Tussilagone, 98%, from Farfarae Flos
(1R,3aR,5R,7S,7aS)-1-(1-acetyloxyethyl)-4-methylidene-2-oxo-7-propan-2-yl-3,3a,5,6,7,7a-hexahydro-1H-inden-5-yl](E)-3-methylpent-2-enoate
2-Pentenoic acid, 3-methyl-, (1S,3aR,5R,7S,7aS)-1-[(1R)-1-(acetyloxy)ethyl]octahydro-4-methylene-7-(1-methylethyl)-2-oxo-1H-inden-5-yl ester, (2E)- | [Molecular Formula]
C23H34O5 | [MDL Number]
MFCD32004666 | [MOL File]
104012-37-5.mol | [Molecular Weight]
390.51 |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder, soluble in ether, chloroform, ethyl acetate, methanol, insoluble in water, derived from the flower bud of Asteraceae Tussilago farfara, Senecio kleinia Less root. | [Biological Activity]
Tussilagone, the main active ingredient of Tussilago farfara, has anti-inflammatory properties. It ameliorates the inflammatory response of dextran sulfate sodium-induced colitis in mice. | [in vivo]
Tussilagone administration (1 mg/kg and 10 mg/kg) produced decreased mortality and lung injury in CLP-activated septic mice. Augmented expression of cyclooxygenase (COX)-2 and TNF-α in pulmonary alveolar macrophages of septic mice were attenuated by tussilagone administration. |
|
|